Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain
<p>Abstract</p> <p>Background</p> <p>The genus <it>Ebolavirus </it>includes five distinct viruses. Four of these viruses cause hemorrhagic fever in humans. Currently there are no licensed vaccines for any of them; however, several vaccines are under developm...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-01-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | http://www.virologyj.com/content/9/1/32 |
| _version_ | 1818824531986350080 |
|---|---|
| author | Ou Wu Delisle Josie Jacques Jerome Shih Joanna Price Graeme Kuhn Jens H Wang Vivian Verthelyi Daniela Kaplan Gerardo Wilson Carolyn A |
| author_facet | Ou Wu Delisle Josie Jacques Jerome Shih Joanna Price Graeme Kuhn Jens H Wang Vivian Verthelyi Daniela Kaplan Gerardo Wilson Carolyn A |
| author_sort | Ou Wu |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The genus <it>Ebolavirus </it>includes five distinct viruses. Four of these viruses cause hemorrhagic fever in humans. Currently there are no licensed vaccines for any of them; however, several vaccines are under development. Ebola virus envelope glycoprotein (GP<sub>1,2</sub>) is highly immunogenic, but antibodies frequently arise against its least conserved mucin-like domain (MLD). We hypothesized that immunization with MLD-deleted GP<sub>1,2 </sub>(GPΔMLD) would induce cross-species immunity by making more conserved regions accessible to the immune system.</p> <p>Methods</p> <p>To test this hypothesis, mice were immunized with retrovirus-like particles (retroVLPs) bearing Ebola virus GPΔMLD, DNA plasmids (plasmo-retroVLP) that can produce such retroVLPs <it>in vivo</it>, or plasmo-retroVLP followed by retroVLPs.</p> <p>Results</p> <p>Cross-species neutralizing antibody and GP<sub>1,2</sub>-specific cellular immune responses were successfully induced.</p> <p>Conclusion</p> <p>Our findings suggest that GPΔMLD presented through retroVLPs may provide a strategy for development of a vaccine against multiple ebolaviruses. Similar vaccination strategies may be adopted for other viruses whose envelope proteins contain highly variable regions that may mask more conserved domains from the immune system.</p> |
| first_indexed | 2024-12-18T23:57:22Z |
| format | Article |
| id | doaj.art-ff4c7695b4c84f849d8c469aa2a433ce |
| institution | Directory Open Access Journal |
| issn | 1743-422X |
| language | English |
| last_indexed | 2024-12-18T23:57:22Z |
| publishDate | 2012-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Virology Journal |
| spelling | doaj.art-ff4c7695b4c84f849d8c469aa2a433ce2022-12-21T20:46:38ZengBMCVirology Journal1743-422X2012-01-01913210.1186/1743-422X-9-32Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domainOu WuDelisle JosieJacques JeromeShih JoannaPrice GraemeKuhn Jens HWang VivianVerthelyi DanielaKaplan GerardoWilson Carolyn A<p>Abstract</p> <p>Background</p> <p>The genus <it>Ebolavirus </it>includes five distinct viruses. Four of these viruses cause hemorrhagic fever in humans. Currently there are no licensed vaccines for any of them; however, several vaccines are under development. Ebola virus envelope glycoprotein (GP<sub>1,2</sub>) is highly immunogenic, but antibodies frequently arise against its least conserved mucin-like domain (MLD). We hypothesized that immunization with MLD-deleted GP<sub>1,2 </sub>(GPΔMLD) would induce cross-species immunity by making more conserved regions accessible to the immune system.</p> <p>Methods</p> <p>To test this hypothesis, mice were immunized with retrovirus-like particles (retroVLPs) bearing Ebola virus GPΔMLD, DNA plasmids (plasmo-retroVLP) that can produce such retroVLPs <it>in vivo</it>, or plasmo-retroVLP followed by retroVLPs.</p> <p>Results</p> <p>Cross-species neutralizing antibody and GP<sub>1,2</sub>-specific cellular immune responses were successfully induced.</p> <p>Conclusion</p> <p>Our findings suggest that GPΔMLD presented through retroVLPs may provide a strategy for development of a vaccine against multiple ebolaviruses. Similar vaccination strategies may be adopted for other viruses whose envelope proteins contain highly variable regions that may mask more conserved domains from the immune system.</p>http://www.virologyj.com/content/9/1/32EbolaEbolavirusEnvelope glycoproteinFilovirusMucin-like domainRetrovirusVirus-like particlesDNA vaccine |
| spellingShingle | Ou Wu Delisle Josie Jacques Jerome Shih Joanna Price Graeme Kuhn Jens H Wang Vivian Verthelyi Daniela Kaplan Gerardo Wilson Carolyn A Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain Virology Journal Ebola Ebolavirus Envelope glycoprotein Filovirus Mucin-like domain Retrovirus Virus-like particles DNA vaccine |
| title | Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain |
| title_full | Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain |
| title_fullStr | Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain |
| title_full_unstemmed | Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain |
| title_short | Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain |
| title_sort | induction of ebolavirus cross species immunity using retrovirus like particles bearing the ebola virus glycoprotein lacking the mucin like domain |
| topic | Ebola Ebolavirus Envelope glycoprotein Filovirus Mucin-like domain Retrovirus Virus-like particles DNA vaccine |
| url | http://www.virologyj.com/content/9/1/32 |
| work_keys_str_mv | AT ouwu inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT delislejosie inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT jacquesjerome inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT shihjoanna inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT pricegraeme inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT kuhnjensh inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT wangvivian inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT verthelyidaniela inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT kaplangerardo inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain AT wilsoncarolyna inductionofebolaviruscrossspeciesimmunityusingretroviruslikeparticlesbearingtheebolavirusglycoproteinlackingthemucinlikedomain |